Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab

Daratumumab Subcutaneous Pre-approval Access Study

Status

APPROVED_FOR_MARKETING

Phases

Unknown

Study type

Expanded Access

Source

ClinicalTrials.gov

Registry ID

NCT04264884

Enrollment

Unknown

Registered

2020-02-11

Start date

Unknown

Completion date

Unknown

Last updated

2020-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.

DRUGDaratumumab

Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.